POSSIBILITIES FOR MEDICAL PREVENTION OF OVARIAN HYPERSTIMULATION SYNDROME


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review presents an update on the role of vascular endothelial (VE) growth factor (VEGF) in the pathogenesis of ovarian hyperstimulation syndrome (OHSS). The paper shows the pathophysiological bases for the development of this iatrogenic complication: hypovolemia, hemoconcentration, dysproteinemia. VEGF receptor-1 (Flt-1) and VEGF receptor-2 (KDR), VE cadherins are considered to be involved in the development of OHSS. Particular attention is given to the effect of dopamine D2-receptor agonists on the basic pathophysiological mechanism of OHSS - vascular permeability. Data on the efficacy of this group of agents in the prevention of this complication are given. It is emphasized that the use of dopamine D2-receptor agonists needs further investigation in order to define their ultimate place in the prevention of OHSS.

Full Text

Restricted Access

About the authors

S. V FETISOVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: svfetisova@mail.ru

I. E KORNEEVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: irina.korneeva@inbox.ru

References

  1. Регистр ВРТ Российской ассоциации репродукции человека. Отчет за 2010 год. СПб.; 2012.
  2. Delvigne A., Rosenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum. Reprod. Update. 2002; 8: 559-77.
  3. Сароян Т.Т. Особенности течения беременности у женщин с тяжелой формой синдрома гиперстимуляции яичников: Автореф. дис.. канд. мед.наук. М.; 2009. 25 с.
  4. De Sutter P., Gerris J., Dhont M. Assisted reproductive technologies: how to minimize the risks and complications in developing countries. Oxford Journals. ESHRE Monographs. 2008; 1: 73-6.
  5. Kol S., Solt I. GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy? J. Assist. Reprod. Genet. 2008; 25: 63-6.
  6. Aboulghar M. Symposium: update on prediction and management of OHSS prevention of OHSS. Reprod. Biomed. Online. 2009; 19: 33-42.
  7. Garcia-Velasco J.A., Isaza V., Quea G, Pellicer A. Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing. Fertil. Steril. 2006; 85: 547-54.
  8. Edwards R.G. IVF, IVM, natural cycle IVF, minimal stimulation. Reprod. Biomed. Online. 2007; 15: 106-19.
  9. Loutradis D, Kiapekou E, Zapanti E, Antsaklis A. Oocyte maturation in assisted reproductive techniques. Ann. N. Y. Acad. Sci. 2006; 1092: 235-46.
  10. Gomez R., Simon C, Remohi' J., Pellicer A. Administration of moderate and high doses of gonadotrophins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biol. Reprod. 2003; 68: 2164-71.
  11. Gomez R., Simon C., Remohi J., Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology. 2002; 143: 4339-48.
  12. Soares S.R. Etiology of OHSS and use of dopamine agonists. Fertil. Steril. 2012; 97(3): 517-22.
  13. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature. 2005; 438: 967-74.
  14. Gille H., Kowalski J., Li B., Le Couter J., Moffat B., Zioncheck T.F. et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. 2001; 276(5): 3222-30.
  15. Bazzoni G., Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol. Rev. 2004; 84: 869-901.
  16. Soares S.R., Gomez R., Simon С. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum. Reprod. Update. 2008; 14(4): 321-33.
  17. Mathur R.S., Jenkins J.M. Is ovarian hyperstimulation syndrome associated with a poor obstetric outcome? Br. J. Obstet. Gynaecol. 2000; 107: 943-6.
  18. Papaleo E., Doldi N., De Santis L. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Hum. Reprod. 2001; 16(11, Pt l): 2263-6.
  19. Basu S., Nagy J.A., Pal S., Vasile E., Eckelhoefer I.A., Bliss V.S. et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat. Med. 2001; 7: 569-74.
  20. Каберголин. В кн.: Справочник лекарственных средств РЛС. М.; 2009. http://www.rlsnet.ru/tn_index_id_42225.htm
  21. Pauli S.A., Tang H., Wang J., Bohlen P., Posser R., Hartman T. et al. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology. 2005; 146: 1301-11.
  22. Gomez R., Gonzalez-Izquierdo M., Zimmermann R.C., Novella-Maestre E., Alonso-Muriel I., Sanchez-Criado J. et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology. 2006; 147: 5400-11.
  23. Alvarez C., Alonso-Muriel I., Garcia G., Crespo J., Bellver J., Simon C. et al. Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome (OHSS) in women undergoing ART: a pilot study. Hum. Reprod. 2007; 22: 3210-4.
  24. Ricci E., Parazzini F., Motta T., Ferrari C.I., Colao A., Clavenna A. et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod. Toxicol. 2002; 16: 791-3.
  25. Alvarez C., Marti-Bonmati L., Novella-Maestre E., Sanz R, Gomez R., Fernandez-Sanchez M. et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J. Clin. Endocrinol. Metab. 2007; 92: 2931-7.
  26. Ciccarelli E., Grottoli S., Razzore P., Gaia D., Bertagna A., Cirillo S. et al. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J. Endocrinol. Invest. 1997; 20(9): 547-51.
  27. Colao A., Abs R., Barcena D.G., Chanson P., Paulus W, Kleinberg D.L. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin. Endocrinol. 2008; 68(1): 66-71.
  28. Жукова Э.В. Беременность, роды и перинатальные исходы у больных с синдромом гиперпролактинемии: Автореф. дис.. канд. мед. наук. М.; 2002. 25с.
  29. Bhangoo R., Karunis M., Ballas J., San Roman G.A., Stelling J.R. Cabergoline decreases the risk of ovarian hyperstimulation syndrome and has no effect on pregnancy rate during in vitro fertilization. Fertil. Steril. 2008; 90 (Suppl.): S237; P-387.
  30. Carizza C., Abdelmassih V., Abdelmassih S., Ravizzini P., Salgueiro L., Salgueiro P.T. et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod. Biomed. Online. 2008; 17: 751-5.
  31. Youssef M.A.F.M., Van Wely M., Hassan M.A., Al-Inany H.G., Mochtar M., Khattab S. et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum. Reprod. Update. 2010; 16: 459-66.
  32. Rollene N., Amols M.H., Hudson S.B.A., Coddington C.C. Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and a gonadotropin releasing-hormone antagonist: a case series. Fertil. Steril. 2009; 92: 1169; e15-7.
  33. Kumar P., Sait S.F., Sharma A., Kumar M. Ovarian hyperstimulation syndrome. J. Hum. Reprod. Sci. 2011; 4(2): 70-5.
  34. Shaltout A., Shohyab A., Youssef M.A. Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012; 165(2): 254-8.
  35. Tang H., Hunter T., Hu Y., Zhai S.D., Sheng X., Hart R.J. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst. Rev. 2012; (2): CD008605.
  36. Tehraninejad E.S., Hafezi M., Arabipoor A., Aziminekoo E., Chehrazi M., Bahmanabadi A. Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial. J. Assist. Reprod. Genet. 2010; 29: 259-64.
  37. Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N. Engl. J. Med. 2007; 356: 39-46.
  38. Kars M., Delgade V., Holman E.R., Feelders R.A., Smit J.W.A., Romijn J.A. et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J. Clin. Endocrinol. Metab. 2008; 93: 3348-56.
  39. Antonini A., Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol. 2007; 6: 826-9.
  40. Busso C., Fernandez-Sanchez M., Garcia-Velasco J.A., Landeras J., Ballesteros A., Munoz E. et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum. Reprod. 2010; 25: 995-1004.
  41. Sherwal V., Malik S., Bhatia V. Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction. J. Hum. Reprod. Sci. 2010; 3: 85-90.
  42. Spitzer D., Wogatzky J., Murtinger M., Zech M.H., Haidbauer R., Zech N.H. Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome. Fertil. Steril. 2011; 95: 2742-4.
  43. Осипова А.А. Агонисты дофамина - парлодел, норпролак и достинекс в коррекции нарушений репродуктивной системы у пациенток с пролактиномами гипофиза. Consilium medicum. 2001; 3(4): 19-23.
  44. Beltrame A.L., Serafini P., Motta A., Soares J.M. Jr., Baracat E.C. The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study. Gynecol. Endocrinol. 2012; Nov 20. Epub ahead of print.
  45. Aflatoonian A., Ghandi S., Soleimani M. et al. Comparison of coasting with cabergolin administration for prevention of severe OHSS in ART cycles. Hum. Reprod. 2007; 22(Suppl.1): abstr.131.
  46. Сафронова Е.В. Синдром гиперстимуляции яичников в программе экстракорпорального оплодотворения (прогнозирование, профилактика): Автореф. дис.. канд. мед. наук. Ростов-на-Дону; 2008. 25с.
  47. Arslan M., Bocca S., Jones E., Mayer J., Stadtmauer L., Oehninger S. Effect of coasting on the implantation potential of embryos transferred after cryopreservation and thawing. Fertil. Steril. 2005; 84(4): 867-74.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies